Company Overview and News
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TORONTO, June 18, 2018 (GLOBE NEWSWIRE) -- Dividend 15 Split Corp. (TSX:DFN) (TSX:DFN.PR.A) (the “Company”) is pleased to announce that 139,327 and 133,180 freely-tradeable common shares of BCE Inc. and TransCanada Corporation, respectively, were tendered pursuant to the exchange offer announced on June 7, 2018 whereby the Company offered 5.55 Class A Shares in exchange for each freely-tradable common share of BCE Inc.
BCE DFN TRP CIX CIFAF
BCE Inc. (BCE - Free Report) recently inked a deal with Superior Propane to offer a comprehensive fuel tank monitoring solution for its clients. The contract for an undisclosed amount is likely to strengthen BCE’s position as a prime provider of state-of-the-art products for the Internet of Things (IoT) market. Superior Propane is a leading supplier of portable fuels, equipment, and services to residential, commercial and industrial customers to more than 10,000 communities in Canada.
BCE MSI CMTL SPG.PRJ BCEXF UBNT SPG SPB SUUIF
Overseas WallStar telecom firms remained at the top by gains this month as North American telcos were mid-bound in analyst 1yr. targeting.
BT.A ORAN SKMD CHLKF VOD VOD CMCSA SKM CTL BTGOF BT VEON 0941 BCE CNSL CHL VODPF
Roth IRAs are going to be the most fun to write about of any of the postings in this series. There are just so many benefits to Roth accounts that they are fun to think about. It isn't just about taxes, but they're good place to start.
PG BLT XOM ENB TD BCE HON WELL INTC GG MCD ABBV MMM F GE BHPBF ENB BHP JNJ BBL VZ MSFT ABBV BHP BA BHPLF
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Dividend 15 Split Corp. declares its 170th consecutive monthly distribution of $0.10000 for each Class A share ($1.20 annually) and $0.04375 for each Preferred share ($0.525 annually). Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018.
MFC.PR.B SLF MFC.PR.F MFC.PR.C TAC CIFAF TD BCE SLF.PR.G SLF.PR.B TD SLF.PR.E SLF.PR.D TRP TNTTF SLF MFC 0945 MFC.PR.I CIX TRI MFC.PR.J MFC MFC.PR.H SLFYF MFC.PR.M MFC.PR.N MFC.PR.K TU MFC.PR.L SLF
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Dividend 15 Split Corp. II ("Dividend 15 II") declares its regular monthly distribution of $0.04375 for each Preferred share. Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018.
MFC.PR.B SLF MFC.PR.F MFC.PR.C TAC CIFAF BCE SLF.PR.G SLF.PR.B SLF.PR.E SLF.PR.D TRP DF SLF MFC 0945 MFC.PR.I CIX TRI MFC.PR.J MFC MFC.PR.H SLFYF MFC.PR.M MFC.PR.N MFC.PR.K TU MFC.PR.L SLF
Putting higher-yielding parts of the portfolio in traditional IRAs can delay any impact from the RMD.
LMT GIS BLT XOM AMT.PRB HTA AMT.PRA BCE AMT HON TRP TRP UPS BHPBF KMB T BHP BBL NVS VZ MSFT DLR BHP QCOM BHPLF CLX
The federal competition watchdog says he wants to "shine a light" on Canada's broadband internet providers with the public's comments on a market that is predominantly served by traditional phone and cable companies.
BCE RCIAF RCI SJR.B BCEXF SJR SJRWF SJR.PR.A TU SJR.A
Form 6K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2018 Commission File Numbe
Form 6K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2018 Commiss
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
BCE BCEXF TRI
Telecom has had a rough year, largely thanks to concerns over cord cutting, a price war in wireless, and rising interest rates.
RCI SJR.B SJR SJRWF SJR.A BCE CHTR RCIAF FTRPR SJR.PR.A MOBAF TU FTR
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to BCE / BCE Inc. on message board site Silicon Investor.
|BCE Blue chip growth stock||FBCE|
|BCE Emergis - global e-commerce||FBCE: Fibercore Inc.|
|BCE - BELL CANADA Holding Co. Now Deserves More Attention_|
as of ET